Johnson & Johnson 미래 성장

Future 기준 확인 2/6

Johnson & Johnson (는) 각각 연간 10.6% 및 3.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 12.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 32.7% 로 예상됩니다.

주요 정보

10.6%

수익 성장률

12.6%

EPS 성장률

Pharmaceuticals 수익 성장	19.6%
매출 성장률	3.3%
향후 자기자본 수익률	32.7%
애널리스트 커버리지	Good
마지막 업데이트	19 Nov 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

LSE:0R34 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	94,695	22,291	22,211	26,879	20
12/31/2025	91,329	20,759	22,459	26,352	22
12/31/2024	88,784	17,499	17,578	22,345	21
9/29/2024	87,696	14,767	19,025	25,146	N/A
6/30/2024	86,576	16,382	19,833	24,642	N/A
3/31/2024	85,648	17,072	18,234	23,191	N/A
12/31/2023	85,159	13,326	17,778	22,791	N/A
10/1/2023	83,703	12,421	15,737	20,278	N/A
7/2/2023	82,348	12,422	14,547	19,073	N/A
4/2/2023	77,458	10,730	16,207	20,472	N/A
1/1/2023	79,990	16,370	17,185	21,194	N/A
10/2/2022	84,855	17,879	17,739	21,576	N/A
7/3/2022	88,197	17,236	19,950	23,582	N/A
4/3/2022	94,880	19,830	19,733	23,315	N/A
1/2/2022	78,740	17,801	19,758	23,410	N/A
10/3/2021	91,446	17,880	22,461	26,021	N/A
7/4/2021	89,190	17,767	22,564	26,114	N/A
4/4/2021	84,214	15,115	20,853	24,252	N/A
1/3/2021	82,584	14,714	20,189	23,536	N/A
9/27/2020	80,856	16,986	18,307	21,591	N/A
6/28/2020	80,503	15,185	17,443	20,735	N/A
3/29/2020	82,729	17,166	19,764	23,231	N/A
12/29/2019	82,059	15,119	19,918	23,416	N/A
9/29/2019	81,706	14,151	19,706	23,262	N/A
6/30/2019	81,325	16,332	18,377	22,007	N/A
3/31/2019	81,593	14,679	18,470	22,138	N/A
12/30/2018	81,581	15,297	18,531	22,201	N/A
9/30/2018	81,382	1,542	18,470	22,062	N/A
7/1/2018	80,684	1,372	N/A	22,056	N/A
4/1/2018	78,693	1,245	N/A	21,749	N/A
12/31/2017	76,450	1,300	N/A	21,056	N/A
10/1/2017	74,361	15,827	N/A	21,604	N/A
7/2/2017	72,531	16,335	N/A	20,699	N/A
4/2/2017	72,174	16,505	N/A	19,491	N/A
1/1/2017	71,890	16,540	N/A	18,767	N/A
10/2/2016	71,595	15,941	N/A	17,199	N/A
7/3/2016	70,877	15,027	N/A	17,978	N/A
4/3/2016	70,182	15,546	N/A	18,886	N/A
1/3/2016	70,074	15,409	N/A	19,569	N/A
9/27/2015	70,517	14,715	N/A	18,849	N/A
6/28/2015	71,882	16,106	N/A	17,363	N/A
3/29/2015	73,590	15,916	N/A	17,420	N/A
12/28/2014	74,331	16,323	N/A	18,710	N/A
9/28/2014	74,232	17,321	N/A	18,245	N/A
6/29/2014	73,340	15,554	N/A	19,538	N/A
3/30/2014	71,722	15,061	N/A	19,060	N/A
12/29/2013	71,312	13,831	N/A	17,414	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 0R34 의 연간 예상 수익 증가율( 10.6% )이 saving rate( 2.1% 보다 높습니다. ).

수익 vs 시장: 0R34 의 연간 수익( 10.6% ) UK 시장( 14.6% 보다 느리게 성장할 것으로 예상됩니다. 14.6% 연간).

고성장 수익: 0R34 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: 0R34 의 수익(연간 3.3% ) UK 시장( 3.5% 보다 느리게 성장할 것으로 예상됩니다. 3.5% 연간).

고성장 수익: 0R34 의 수익(연간 3.3% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 0R34 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 32.7 %)

Johnson & Johnson 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Johnson & Johnson Seeks U.S. FDA Approval for Subcutaneous Induction Regimen of Tremfya (Guselkumab) inulcerative Colitis, A First for an IL-23 Inhibitor

Upcoming dividend of US$1.24 per share

Johnson & Johnson Announces Results from Additional Analyses of the Phase 2 DAHLIA Study Highlighting Improvement in Key Measures of Disease Activity and IgG Reduction

Johnson & Johnson Announces U.S. Food and Drug Administration Grants Nipocalimab Breakthrough Therapy Designation for the Treatment of Adults Living with Moderate-To-Severe Sjogren's Disease

Johnson & Johnson Submits Applications in the U.S. and EU Seek Approval of DARZALEX FASPRO® as Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma

Johnson & Johnson Announces Results from Phase 3 GRAVITI Study of Tremfya

Johnson & Johnson Highlights Innovative Neuropsychiatry Portfolio and Pipeline at Psych Congress

Johnson & Johnson Announces New Spectrem Study Findings Reveal Tremfya (Guselkumab) Effectively Clears Overlooked and Undertreated Plaque Psoriasis

Third quarter dividend of US$1.24 announced

Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & Johnson

Third quarter 2024 earnings released: EPS: US$1.11 (vs US$1.71 in 3Q 2023)

Johnson & Johnson Announces Positive Results from the Phase 2/3 Vibrance-MG Study of Nipocalimab

Johnson & Johnson Announces Tremfya Data in Both Crohn's Disease and Ulcerative Colitis

Johnson & Johnson Announces the Results of A Landmark Real-World, Head-To-Head Study Showing That Erleada (Apalutamide)

Johnson & Johnson Files for U.S. FDA Approval of DARZALEX FASPRO-Based Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Patients for Whom Transplant Is Not Planned

Johnson & Johnson Announces Data from Three Studies Highlighting Clinical Efficacy of Darzalex® (Daratumumab) and Darzalex Faspro in Maintenance Regimens

Johnson & Johnson Announces Interim Data from the Ongoing Phase 2 Sunrise-4 Study Showing Neoadjuvant Treatment with Investigational Tar-200 Plus Cetrelimab

Johnson & Johnson Announces Updated Results from the Phase 3 Mariposa-2 Study Which Showed Rybrevant (Amivantamab-Vmjw)

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Johnson & Johnson to Report Q4, 2024 Results on Jan 22, 2025

Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis

Johnson & Johnson Announces Executive Changes

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze™ (Lazertinib)

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견